Growth factor receptor-bound protein 2 mRNA
Nucleic acid in Homo sapiens that 1 drug acts on.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Other 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Prexigebersen | Phase 2 | Bio-Path Holdings, Inc. | Oligonucleotide | Antisense inhibitorGrowth factor receptor-bound protein 2 mRNA antisense inhibitor | 2 |
| BP1001-A in Patients With Advanced or Recurrent Solid Tumors | Prexigebersen | Phase 1 | Recruiting | Bio-Path Holdings, Inc. | Dec 12, 2019 |
| Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML | Prexigebersen | Phase 2 | Recruiting | Bio-Path Holdings, Inc. | May 25, 2016 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4627241, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets